Regardless of ejection fraction, it is uncertain if the sodium-glucose cotransporter 2 inhibitor dapagliflozin lowers the chance of a variety of illnesses and death, resulting in patients having major cardiovascular illnesses.
Most Recent Articles
VISUALIZED: Cardiac Assessments by Measuring Biomarkers to Evaluate Cardiac Pathology Among Individuals Infected With COVID-19
Read further: Cardiac Assessments by Measuring Biomarkers to Evaluate Cardiac Pathology Among Individuals Infected With COVID-19
Cardiac Assessments by Measuring Biomarkers to Evaluate Cardiac Pathology Among Individuals Infected With COVID-19
As many as 30% of people may experience unique, reoccurring, or persistent health issues for many weeks after having SARS-CoV-2.1 So-called protracted COVID may manifest in people with a wide range of initial symptoms, from...
Comparison of Recommendations for Statin Use for ASCVD Prevention
The guidelines of USPSTF provide recommendations for the use of statin therapy for the prevention of atherosclerotic cardiovascular disease (ASCVD) for adults of 40-75 years of age with equal or greater than 1 CVD risk factor...
Guidelines Regarding the Use of Coronary Artery Calcium Score
This article summarizes the guidelines regarding the use of the global coronary artery calcium (CAC) score. The following are the main key points:
